Penicillin changed the world. NNVC's drug could too.

This public company's one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market

We might not have to imagine it much longer. This company's leading drug candidate could completely transform the way viruses and their variants are treated worldwide. To put it simply, NV-387 could revolutionize antiviral treatment just as antibiotics did against bacteria.

There is a significant unmet medical need for a broad-spectrum antiviral drug that is effective and useable in all segments of the population- from pediatric to elderly patients. Not only this, but this innovative approach can work even when viruses mutate.

With its ongoing expansion and development of its diverse and promising product pipeline, this biotech is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.

The world is changing and so are our viruses. Learn more about the company that could largely benefit your bottom line, as well as the health of our global population.

This message is a paid advertisement for NanoViricides Inc., (NYSE: NNVC) from Interactive Offers. It's Today Media, LLC. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $7,000.00. Other than the compensation received for this advertisement sent to subscribers, It's Today Media and its principals are not affiliated with Interactive Offers. It's Today Media and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither It's Today Media nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from It's Today Media to buy or sell any security. It's Today Media has not evaluated the accuracy of any claims made in this advertisement. It's Today Media recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides Inc. (NYSE: NNVC) on Interactive Offers' website for additional information about the relationship between Interactive Offers and NanoViricides Inc., (NYSE: NNVC).